

## **Resignation of Non-Executive Director**

**3 January 2023** - **AusCann Group Holdings Limited** (ASX: AC8) ('AusCann' or 'the Company') announces that Mrs Krista Bates has resigned from her position as Non-executive Director of the Company to pursue other corporate interests, following the completion of a 3 year term with AusCann.

Mrs Bates is an experienced and highly credentialed non-executive and executive director of listed companies (Australian Stock Exchange and London Stock Exchange) and played an active role in helping navigate the restructuring of the business as both a director and as interim Chairwoman of AusCann since her appointment in December, 2019.

AusCann Chair, Mr. Tod McGrouther said "During her tenure, Krista has made a substantial contribution to both the AusCann Board and the company. Her expertise in local and international corporate law has been extremely important in helping reposition the AusCann business following significant organisational changes.

On behalf of the directors, AusCann management and the business, I would like to thank Krista for her contribution and support of the Company and wish her well in her other business endeavours".

## **ENDS**

This ASX announcement was authorised for release by the Board of AusCann.

## For more information, please contact:

Tod McGrouther Chair info@auscann.com.au +61 8 6444 1720

## **ABOUT AUSCANN**

**AusCann Group Holdings Limited** (ASX:AC8) is an Australian-based company focused on the development and commercialisation of cannabinoid-derived therapeutic products to address unmet needs for humans and animals within Australia and internationally. Our key difference is the commitment to rigorous product development, focused on providing reliable, stable and standardised cannabinoid-derived therapeutics products, whilst generating robust safety, quality assurance and efficacy data to support market access in various regulatory environments around the world.